Effect of urotensin II on the nitric oxide production in neonatal rat cardiomyocytes

Acta Physiologica Sinica

Volumn 54, Issue 4, 2002, Pages 307-310

  Li, Ling ^a   Yuan, Wen Jun ^a   Pan, Xiu Jie ^a   Wang, Wei Zhong ^a   Qiu, Jing Wei ^a   Tang, Chao Shu ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Cardiomyocytes; Endothelial nitric oxide synthase; Nitric oxide; Reverse transcription polymerase chain reaction; Urotensins

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NOS3 PROTEIN, RAT; UROTENSIN; UROTENSIN II;

ANIMAL; CELL CULTURE; DRUG EFFECTS; HEART MUSCLE CELL; METABOLISM; NEWBORN; RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; UROTENSINS;

EID: 11244325804     PISSN: 03710874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Coulouarn Y, Lihrman I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Cordon JM, Bern HA, Vaudry H. Cloning of cDNA encoding the urotensin D precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998,95:15803-15808.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AN, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, Mcnulty DE, Ellis CE, Elshouragy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin- II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 1999,401(6750):282-286.
3. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol, 2001,132:5-9.
4. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med, 2000,10:229-237.
5. Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol, 1999,276(1 Pt 2): R265-R276.
6. Maclean MR, Alexander D, Seirrar A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Pollard K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol, 2000,130:201-204.
7. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci, 2001,69:175-180.
8. Katano Y, Ishihata A, Aita T, Ogaki T, Hone T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol, 2000,402(1-2):R5-R7.
9. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol, 2000,131:1262-1274.
10. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hauler BG, Simmons RL. Negative inotropic effects of cytokines 'on the heart mediated by nitric oxide. Science, 1992,257:387-389.